EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study

Weicai Huang iD, Wenjun Xiong, Lei Tang iD, Chuanli Chen, Qingyu Yuan, Cheng Zhang, Kangneng Zhou, Zepang Sun, Taojun Zhang, Zhen Han, Hao Feng, Xiaokun Liang und 8 weitere

Journal for ImmunoTherapy of Cancer · 2023-11 · 11 (11) · e007807

DOI: 10.1136/jitc-2023-007807 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 21.11.2023. Verfasst von Weicai Huang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Southern Medical University Nan…. Hauptthemen laut MEDLINE: Immunotherapy, Stomach Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Cancer, Project funded by China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite remarkable benefits have been provided by immune checkpoint inhibitors in gastric cancer (GC), predictions of treatment response and prognosis remain unsatisfactory, making identifying biomarkers desirable. The aim of this study was to develop and validate a CT imaging biomarker to predict the immunotherapy response in patients with GC and investigate the associated immune infiltration patterns.

Methods

This retrospective study included 294 GC patients who received anti-PD-1/PD-L1 immunotherapy from three independent medical centers between January 2017 and April 2022. A radiomics score (RS) was developed from the intratumoral and peritumoral features on pretreatment CT images to predict immunotherapy-related progression-free survival (irPFS). The performance of the RS was evaluated by the area under the time-dependent receiver operating characteristic curve (AUC). Multivariable Cox regression analysis was performed to construct predictive nomogram of irPFS. The C-index was used to determine the performance of the nomogram. Bulk RNA sequencing of tumors from 42 patients in The Cancer Genome Atlas was used to investigate the RS-associated immune infiltration patterns.

Results

Overall, 89 of 294 patients (median age, 57 years (IQR 48–66 years); 171 males) had an objective response to immunotherapy. The RS included 13 CT features that yielded AUCs of 12-month irPFS of 0.787, 0.810 and 0.785 in the training, internal validation, and external validation 1 cohorts, respectively, and an AUC of 24-month irPFS of 0.805 in the external validation 2 cohort. Patients with low RS had longer irPFS in each cohort (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyStomach NeoplasmsHumansMaleMiddle AgedBiomarkersRetrospective StudiesTomography, X-Ray ComputedFemaleAged

Stichwörter der Autor:innen

Biomarkers, TumorImmunotherapy

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China.
  • Department of Gastrointestinal Surgery, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
  • Department of Radiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
  • Department of Medical Imaging Center, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China.
  • Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
  • University of Science and Technology, Beijing, China.

ORCID-Profile: Weicai Huang, Lei Tang, Lin Shen

Förderung

  • Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Cancer
  • Project funded by China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • Guangdong Provincial Major Talents Project
  • Key-Area Research and Development Program of Guangdong Province

Zitieren

APA

Huang, W., Xiong, W., Tang, L., Chen, C., Yuan, Q., Zhang, C., Zhou, K., Sun, Z., Zhang, T., Han, Z., Feng, H., Liang, X., Zhong, Y., Deng, H., Yu, L., Xu, Y., Wang, W., Shen, L., Li, G., & Jiang, Y. (2023). Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study. Journal for ImmunoTherapy of Cancer, 11(11), e007807. https://doi.org/10.1136/jitc-2023-007807

Vancouver

Huang W, Xiong W, Tang L, Chen C, Yuan Q, Zhang C, et al. Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study. Journal for ImmunoTherapy of Cancer. 2023;11(11):e007807. doi:10.1136/jitc-2023-007807

BibTeX
@article{Huang2023,
  author = {Huang, Weicai and Xiong, Wenjun and Tang, Lei and Chen, Chuanli and Yuan, Qingyu and Zhang, Cheng and Zhou, Kangneng and Sun, Zepang and Zhang, Taojun and Han, Zhen and Feng, Hao and Liang, Xiaokun and Zhong, Yonghong and Deng, Haijun and Yu, Lequan and Xu, Yikai and Wang, Wei and Shen, Lin and Li, Guoxin and Jiang, Yuming},
  title = {Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {11},
  pages = {e007807},
  doi = {10.1136/jitc-2023-007807}
}
Kostenlos starten →